{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05680233",
            "orgStudyIdInfo": {
                "id": "OAS-235i-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "5R44DK101240",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/5R44DK101240"
                }
            ],
            "organization": {
                "fullName": "Oasis Pharmaceuticals, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis",
            "officialTitle": "A Phase 1a/1b Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OA-235i, a PAR2 Inhibitor, in Adults With Nonalcoholic Steatohepatitis",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "safety-study-of-oa-in-subjects-with-nonalcoholic-steatohepatitis"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-12",
            "studyFirstSubmitQcDate": "2023-01-03",
            "studyFirstPostDateStruct": {
                "date": "2023-01-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-05",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Oasis Pharmaceuticals, LLC",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                },
                {
                    "name": "Mayo Clinic",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is a Phase 1, first-in-human single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of OA-235i in subjects with nonalcoholic steatohepatitis.",
            "detailedDescription": "The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single ascending dose (SAD) in participants with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis. This dose-escalating strategy will test the safety of OA-235i when given as a single subcutaneous dosage using up to five successive cohorts. Each cohort will have three non-randomized participants receiving the active medication. One (1) planned multiple dose (MD) expansion dose cohort with 8 NAFLD/NASH subjects will be enrolled for a 7-day dosing regimen at a dose level to be determined from the SAD portion of the study."
        },
        "conditionsModule": {
            "conditions": [
                "Nonalcoholic Steatohepatitis",
                "Nonalcoholic Fatty Liver"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Single ascending dose (SAD) sequential group study of a sc dose of OA-235i in five (5) planned dose cohorts with 3 subjects/cohort administering a bolus injection at escalating dose levels from 4 to 40 mg. One (1) planned multiple dose (MD) expansion dose cohort with 8 NAFLD/NASH subjects will be enrolled for a 7-day dosing regimen at a dose level to be determined from the SAD portion of the study.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "All subjects will be blinded to IP dose/level."
                }
            },
            "enrollmentInfo": {
                "count": 23,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "OA-235i (4-40 mg)",
                    "type": "EXPERIMENTAL",
                    "description": "Single ascending dose (SAD): OA-235i (4-40 mg) administered subcutaneously (SC) once to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis.\n\nMultiple dose (MD): OA-235i (dose level to be determined from SAD) administered subcutaneously (SC) once daily for 7 days to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis.",
                    "interventionNames": [
                        "Drug: OA-235i (4 mg)",
                        "Drug: OA-235i (8 mg)",
                        "Drug: OA-235i Dose 3",
                        "Drug: OA-235i Escalating Dose 4",
                        "Drug: OA-235i Escalating Dose 5",
                        "Drug: OA-235i Multiple Dose"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "OA-235i (4 mg)",
                    "description": "3 participants will receive 4 mg as a single subcutaneous dose",
                    "armGroupLabels": [
                        "OA-235i (4-40 mg)"
                    ],
                    "otherNames": [
                        "PAR2 inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "OA-235i (8 mg)",
                    "description": "3 participants will receive 8 mg as a single subcutaneous dose",
                    "armGroupLabels": [
                        "OA-235i (4-40 mg)"
                    ],
                    "otherNames": [
                        "PAR2 inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "OA-235i Dose 3",
                    "description": "3 participants will receive a single escalating subcutaneous dose",
                    "armGroupLabels": [
                        "OA-235i (4-40 mg)"
                    ],
                    "otherNames": [
                        "PAR2 inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "OA-235i Escalating Dose 4",
                    "description": "3 participants will receive a single escalating subcutaneous dose",
                    "armGroupLabels": [
                        "OA-235i (4-40 mg)"
                    ],
                    "otherNames": [
                        "PAR2 inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "OA-235i Escalating Dose 5",
                    "description": "3 participants will receive a single escalating subcutaneous dose",
                    "armGroupLabels": [
                        "OA-235i (4-40 mg)"
                    ],
                    "otherNames": [
                        "PAR2 inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "OA-235i Multiple Dose",
                    "description": "8 participants will receive a daily subcutaneous dose for 7 consecutive days",
                    "armGroupLabels": [
                        "OA-235i (4-40 mg)"
                    ],
                    "otherNames": [
                        "PAR2 inhibitor"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "Number of participants with treatment-emergent with adverse events (incidence and severity)",
                    "timeFrame": "30 Days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To characterize the OA-235i Pharmacokinetics (PK) by Cmax",
                    "description": "OA-235i PK by peak plasma concentration (Cmax)",
                    "timeFrame": "8 Days"
                },
                {
                    "measure": "To characterize the OA-235i Pharmacokinetics (PK) by t1/2",
                    "description": "OA-235i PK by the terminal elimination half-life (t1/2)",
                    "timeFrame": "8 Days"
                },
                {
                    "measure": "To characterize the OA-235i Pharmacokinetics (PK) by Tmax",
                    "description": "OA-235i PK by time to peak plasma concentration (Tmax)",
                    "timeFrame": "8 Days"
                },
                {
                    "measure": "To characterize the OA-235i Pharmacokinetics (PK) by AUC",
                    "description": "OA-235i PK by area under the plasma concentration versus time curve (AUC)",
                    "timeFrame": "8 Days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Main Inclusion Criteria:\n\n1. Male and female subjects between the ages of 18 and 70 years, inclusive, at Screening.\n2. Body mass index (BMI) of \u226525 and \\<40 kg/m2 with a total body weight 50-150 kg (inclusive) at Screening and Day 1 Pre-dose.\n3. Suspected or confirmed diagnosis of noncirrhotic NAFLD/NASH without advanced hepatic fibrosis by one of the following:\n\n   1. Histologically with liver biopsy within 2 years prior to Screening (documentation with pathology report); or\n   2. Radiologically with \u22655% steatosis measured by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), or controlled attenuation parameter (CAP) \\>288 dB/m via FibroScan assessment, or presence of hepatic steatosis on abdominal ultrasound within 1 year prior to Screening; or\n   3. Clinically with a diagnosis of Metabolic Syndrome (MetS) reflecting the presence of at least 3 of 5 factors/criteria (ie, abdominal obesity, elevated triglycerides, reduced HDL-C, elevated blood pressure, and/or elevated fasting glucose \\[IFG or type 2 diabetes mellitus\\]) as defined by the National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) \\[Grundy 2005\\]; and fatty liver on imaging within 1 year prior to Screening.\n\nKey Exclusion Criteria:\n\n1. History or presence of cirrhosis as assessed by Investigator following review of diagnostic measures (clinical, imaging, histopathology, or laboratory).\n2. Clinical evidence of hepatic decompensation (laboratory or clinical abnormalities- ascites, variceal bleeding, etc.).\n3. History or presence of other concomitant liver disease (eg, hepatitis B \\& C, alcoholic liver disease, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin (A1AT) deficiency, bile duct obstruction, liver primary or metastatic cancer, drug-induced liver disease.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Manal Abdelmalek, MD",
                    "role": "CONTACT",
                    "phone": "507-284-2511",
                    "email": "Abdelmalek.manal@mayo.edu"
                },
                {
                    "name": "Christopher Kigongo",
                    "role": "CONTACT",
                    "phone": "507-226-1998",
                    "email": "Kigongo.Christopher@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Athan Kuliopulos, MD, PhD",
                    "affiliation": "Oasis Pharmaceuticals, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Manal Abdelmalek, MD",
                            "role": "CONTACT",
                            "phone": "507-284-2511",
                            "email": "Abdelmalek.manal@mayo.edu"
                        },
                        {
                            "name": "Christopher Kigongo",
                            "role": "CONTACT",
                            "phone": "507-226-1998",
                            "email": "Kigongo.Christopher@mayo.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Nonalcoholic Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}